Security key
26818M108
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 54,627,733
- Total 13F value
- $628,721,822
- Share change
- +4,908,333
- Put/Call ratio
- 2.8%
- SEC-reported price per share
- $11.52
- Number of holders
- 125
- Value change
- +$56,536,368
- Number of buys
- 74
- Number of sells
- 36
- Shares outstanding
- 164,808,822
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2023
Institutions
125
Top holders
10
DYN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26818M108
Recent filing periods:
Ownership snapshot
Top reported holders of DYN - Dyne Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Life Scienc...
Disclosed value leader
Atlas Venture Life Scienc...
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
Lead comparable stake: 6%
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Life Science Advisors, LLC leads the comparable SEC ownership view at 6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Atlas Venture Life Science Advisors, LLC's linked filing trail.
Comparable ownership
Top 5
Atlas Venture Life Science Adviso...
6%
MPM ASSET MANAGEMENT LLC
3%
CITADEL ADVISORS LLC
1.8%
Deep Track Capital, LP
1.6%
BlackRock Finance, Inc.
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
6%
|
$114,387,308
9,869,483 shares
|
— | 31 Dec 2022 |
| MPM ASSET MANAGEMENT LLC |
13F
Company
|
3%
|
$57,385,602
4,951,303 shares
|
— | 31 Dec 2022 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.8%
|
$33,727,816
2,910,079 shares
|
— | 31 Dec 2022 |
| Deep Track Capital, LP |
13F
Company
|
1.6%
|
$31,109,878
2,684,200 shares
|
— | 31 Dec 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
1.6%
|
$30,349,783
2,618,618 shares
|
— | 31 Dec 2022 |
| WASATCH ADVISORS LP |
13F
Company
|
1.5%
|
$29,201,921
2,519,579 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
125
Shares
54,627,733
Rows available
125
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q1 2023 Across Filers
Q1 2023 holders
125
Q1 2023 holders
125
Holder diff
0
| Investor | Q1 2023 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend